Stonegate Capital Partners Updates Coverage On Aemetis, Inc. (Nasdaq: AMTX) 1Q26
Aemetis’ 1Q26 further supports the transition from project buildout toward recurring low-carbon fuel monetization, with quarterly 45Z recognition and improving RNG economics beginning to appear in reported results. Revenue increased 27% y/y to $54.6M, gross profit improved to $2.8M from a $5.1M loss, and adj. EBITDA improved to negative $1.3M from negative $10.7M. The key […]
Stonegate Capital Partners Updates Coverage On Surf Air Mobility Inc. (NYSE: SRFM) 1Q26
SRFM’s 1Q26 results showed continued execution under the transformation plan, with revenue of $25.6M at the high end of guidance and up 9% y/y, while adjusted EBITDA loss of $12.3M outperformed guidance for a loss of $15.5M to $13.5M. Results were supported by improved On Demand private charter margins, cost controls across airline operations, and […]
Stonegate Capital Partners Updates Coverage on MarketWise (NASDAQGM: MKTW) 1Q26
MKTW’s 1Q26 improved the forward setup by showing that the FY25 recovery is broadening into paid subscriber growth, higher ARPU, and reaffirmed FY26 cash flow targets. The reported GAAP revenue decline and negative CFFO understated underlying operating trends; revenue recognition continues to reflect older billings cohorts given the multi-year recognition structure of subscriptions, while CFFO […]
Stonegate Capital Partners Updates Coverage on Viemed Healthcare, Inc. (NASDAQ: VMD) 1Q26
Viemed’s 1Q26 results showed improving growth quality, not just reported scale. Sleep, resupply, and maternal health are becoming larger contributors, reducing reliance on legacy ventilation and improving capital efficiency. At the same time, ventilation appears to be moving through the NCD transition, with better new-start activity and improving compliance, though turnover continues to pressure census. […]
Stonegate Capital Partners Updates Coverage on OS Therapies Inc. (NYSE: OSTX)
OS Therapies advanced materially through late-stage regulatory and commercialization preparation as OST-HER2 moved from Phase 2b supported planning toward a more defined global approval pathway in recurrent, fully resected, pulmonary metastatic osteosarcoma. The key change is greater regulatory clarity: EMA initiated rolling review of the OST HER2 Conditional Marketing Authorization dossier, while EMA and Australia’s […]
Stonegate Capital Partners Updates Coverage on NU Skin Enterprises Inc. (NYSE: NUS) 1Q26
NUS reported revenue, adj NI, and adj EPS of $320.6M, $6.8M, and $0.14, respectively. This compares to our estimates of $329.7M, $7.7M, and $0.15, respectively. Revenue came in near the low end of guidance, while adjusted EPS remained within range as management continued investing behind Prysm iO and emerging markets while maintaining cost discipline. Core […]
Stonegate Capital Partners Updates Coverage on OppFi, Inc. (NYSE: OPFI) 1Q26
OppFi’s 1Q26 results were steady, but the bigger development was its shift toward a bank-enabled, deposit-funded model through the pending BNCC acquisition. Revenue and receivables grew despite lower originations, as tighter credit, inflation, weaker sentiment, and higher average tax refunds temporarily reduced loan demand. Higher charge-offs pressured adjusted earnings, but expense discipline held as management […]
Stonegate Capital Partners Updates Coverage on BlackSky Technology, Inc. (NYSE: BKSY) 1Q26
BKSY’s 1Q26 marked a clearer Gen-3 commercialization inflection, with accelerating sovereign contract adoption, improving in-year revenue visibility, and management raising FY26 revenue and adj. EBITDA guidance. While reported revenue remained affected by Mission Solutions timing, the more important development was the continued scaling of higher-margin Gen-3 subscription services and the operational expansion of the constellation […]
Stonegate Capital Partners Updates Coverage on Gladstone Commercial Corp. (NasdaqGS: GOOD) 1Q26
GOOD reported revenue, FFO per share, and AFFO per share of $41.9M, $0.35, and $0.30, respectively. This compares to our/consensus estimates of $43.5M/$42.9M, $0.36/$0.35, and $0.25/$0.26. The q/q decline appears largely tied to 4Q25 items, including a lease termination fee and easement settlement, rather than a material change in portfolio quality. While the quarter did […]
Stonegate Capital Partners Updates Coverage on Civeo Corporation (NYSE: CVEO) Q126
CVEO reported revenue and adj EBITDA of $172.7M and $22.5M, respectively. This compares to our/consensus estimates of $154.6M/$154.7M and $16.3M/$16.8M, respectively. Net loss improved to $3.8M from $9.8M in 1Q25, while operating cash flow was $(9.7)M, reflecting typical seasonal working capital use. Capex remained modest at $4.1M and was primarily maintenance-related. The key takeaway is […]